Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $2.43 in the prior trading day, BioAtla Inc (NASDAQ: BCAB) closed at $2.11, down -13.37%. In other words, the price has decreased by -$13.37 from its previous closing price. On the day, 0.8 million shares were traded. BCAB stock price reached its highest trading level at $2.505 during the session, while it also had its lowest trading level at $2.1.
Ratios:
Our goal is to gain a better understanding of BCAB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on September 15, 2022, initiated with a Mkt Outperform rating and assigned the stock a target price of $17.
On May 05, 2022, Credit Suisse Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $35 to $5.
On March 21, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on March 21, 2022, with a $25 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 26 ’23 when MCBRINN SYLVIA bought 4,000 shares for $2.33 per share. The transaction valued at 9,320 led to the insider holds 15,125 shares of the business.
SHORT JAY M PHD bought 50,000 shares of BCAB for $106,910 on Dec 20 ’23. The Chief Executive Officer now owns 1,439,283 shares after completing the transaction at $2.14 per share. On Dec 19 ’23, another insider, STEINMAN LAWRENCE, who serves as the Director of the company, bought 20,000 shares for $2.05 each. As a result, the insider paid 41,048 and bolstered with 38,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAB now has a Market Capitalization of 101243552 and an Enterprise Value of -7767410.
Stock Price History:
The Beta on a monthly basis for BCAB is 1.27, which has changed by -0.3916185 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, BCAB has reached a high of $4.07, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is -25.42%, while the 200-Day Moving Average is calculated to be -9.33%.
Shares Statistics:
The stock has traded on average 530.54K shares per day over the past 3-months and 487790 shares per day over the last 10 days, according to various share statistics. A total of 48.08M shares are outstanding, with a floating share count of 38.77M. Insiders hold about 19.40% of the company’s shares, while institutions hold 54.34% stake in the company. Shares short for BCAB as of 1711584000 were 5588159 with a Short Ratio of 10.53, compared to 1709164800 on 5105828. Therefore, it implies a Short% of Shares Outstanding of 5588159 and a Short% of Float of 12.640001000000002.
Earnings Estimates
The current rating of BioAtla Inc (BCAB) reflects the combined expertise of 4 analysts actively engaged in assessing its market performance.On average, analysts expect EPS of -$0.79 for the current quarter, with a high estimate of -$0.71 and a low estimate of -$1, while EPS last year was -$0.63. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.44 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$2.74 and -$2.78 for the fiscal current year, implying an average EPS of -$2.76. EPS for the following year is -$1.93, with 5 analysts recommending between -$1.78 and -$2.14.
